Oyavas (Bevacizumab)

Bevacizumab, the active ingredient in Oyavas, is a monoclonal antibody presented as a 100 mg/4 ml solution for intravenous use. It treats various solid tumours by inhibiting angiogenesis in adult oncology patients. GNH USA supplies Oyavas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Oyavas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oyavas is a VEGF‑targeting therapy used in several oncology indications where angiogenesis drives disease progression.

- Colorectal cancer: improves survival when combined with chemotherapy in metastatic disease. - Non‑small cell lung cancer: enhances response rates in combination regimens for advanced disease. - Glioblastoma multiforme: prolongs progression‑free interval when added to radiotherapy. - Ovarian cancer: increases progression‑free survival in recurrent disease. - Cervical cancer: used with chemotherapy for persistent, recurrent or metastatic tumours. - Renal cell carcinoma: part of combination protocols for advanced disease.

Adverse reactions to bevacizumab vary from mild to severe and are monitored throughout therapy.

Common Side Effects: - Hypertension: elevated blood pressure requiring medical management. - Proteinuria: presence of protein in urine, often transient. - Bleeding: epistaxis, gum bleeding or minor bruising. - Wound healing complications: delayed closure after surgery. - Fatigue: generalised tiredness reported by patients. - Gastrointestinal perforation: rare abdominal pain with signs of peritonitis.

Serious or Rare Side Effects: - Arterial thromboembolism: risk of heart attack or stroke. - Severe hemorrhage: gastrointestinal or intracranial bleeding. - Severe wound dehiscence: postoperative wound breakdown. - Nephrotic syndrome: significant protein loss leading to swelling. - Posterior reversible encephalopathy syndrome (PRES): neurological changes with imaging findings. - Fatal infusion reactions: anaphylaxis or severe hypersensitivity.

Bevacizumab requires careful monitoring and specific safety measures before and during treatment.

- Blood pressure monitoring: check and control hypertension before each infusion. - Renal function assessment: evaluate proteinuria and kidney health regularly. - Bleeding risk assessment: review patient history of hemorrhage or anticoagulant use. - Surgical planning: avoid elective surgery within 28 days of the last dose. - Pregnancy and lactation: contraindicated; avoid use in pregnant or nursing women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bevacizumab may interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Anticoagulants: increased risk of severe bleeding. - Antiplatelet agents: heightened hemorrhagic potential. - High‑dose aspirin: may exacerbate bleeding complications.

Moderate Interactions (Monitor Closely): - Chemotherapy agents (e.g., paclitaxel, carboplatin): may enhance toxicities. - Hypertensive agents: require dose adjustments to control blood pressure. - NSAIDs: can worsen renal impairment and proteinuria.